Merck Signs Agreement with Dr. Falk PharmaGmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody Merck (NYSE: MRK), ...
Merck MRK0.75%increase; green up pointing triangle & Co. said it agreed to acquire Prometheus Biosciences Inc. for $10.8 billion, a push into the lucrative market for immune-disease treatments. Merck ...
Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback